Q3 2025 EPS Estimates for TransMedics Group, Inc. (NASDAQ:TMDX) Boosted by William Blair

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - Equities research analysts at William Blair increased their Q3 2025 earnings per share estimates for shares of TransMedics Group in a research report issued to clients and investors on Tuesday, April 30th. William Blair analyst R. Daniels now forecasts that the company will earn $0.12 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for TransMedics Group's current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group's FY2025 earnings at $0.27 EPS.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million during the quarter, compared to analysts' expectations of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. TransMedics Group's revenue for the quarter was up 132.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.08) EPS.

TMDX has been the subject of several other reports. Piper Sandler reiterated an "overweight" rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. Morgan Stanley raised their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 28th. TD Cowen raised their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Oppenheimer raised their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the company an "outperform" rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $119.00.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $6.84 during mid-day trading on Thursday, hitting $124.44. The stock had a trading volume of 1,399,409 shares, compared to its average volume of 756,299. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $124.52. The company's 50 day simple moving average is $83.85 and its 200 day simple moving average is $75.92. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group during the first quarter worth $30,000. Fidelis Capital Partners LLC acquired a new position in TransMedics Group in the first quarter valued at $35,000. Cutler Group LLC CA lifted its holdings in TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company's stock valued at $38,000 after buying an additional 600 shares during the period. First Horizon Advisors Inc. increased its position in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company's stock worth $83,000 after acquiring an additional 222 shares in the last quarter. Finally, RiverPark Advisors LLC bought a new stake in shares of TransMedics Group during the third quarter worth about $60,000. 99.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 736 shares of TransMedics Group stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now directly owns 14,375 shares in the company, valued at $1,295,043.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares in the company, valued at $721,273. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 736 shares of TransMedics Group stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company's stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Insiders sold 102,078 shares of company stock worth $8,691,221 over the last three months. Insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.